CA2048673A1 - Effets metaboliques du facteur d'inhibition de la leucemie sur les os - Google Patents

Effets metaboliques du facteur d'inhibition de la leucemie sur les os

Info

Publication number
CA2048673A1
CA2048673A1 CA002048673A CA2048673A CA2048673A1 CA 2048673 A1 CA2048673 A1 CA 2048673A1 CA 002048673 A CA002048673 A CA 002048673A CA 2048673 A CA2048673 A CA 2048673A CA 2048673 A1 CA2048673 A1 CA 2048673A1
Authority
CA
Canada
Prior art keywords
lif
bone
cells
animal
polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002048673A
Other languages
English (en)
Inventor
Donald Metcalf
Ian R. Reid
Thomas J. Martin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Innovation Pty Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2048673A1 publication Critical patent/CA2048673A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2093—Leukaemia inhibitory factor [LIF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002048673A 1989-03-07 1990-03-06 Effets metaboliques du facteur d'inhibition de la leucemie sur les os Abandoned CA2048673A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AUPJ309189 1989-03-07
AUPJ3091 1989-03-07
AUPJ474289 1989-06-15
AUPJ4742 1989-06-15

Publications (1)

Publication Number Publication Date
CA2048673A1 true CA2048673A1 (fr) 1990-09-08

Family

ID=25643646

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002048673A Abandoned CA2048673A1 (fr) 1989-03-07 1990-03-06 Effets metaboliques du facteur d'inhibition de la leucemie sur les os

Country Status (5)

Country Link
EP (1) EP0463004A4 (fr)
JP (1) JP3055802B2 (fr)
CA (1) CA2048673A1 (fr)
NZ (1) NZ232826A (fr)
WO (1) WO1990010454A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL97779A (en) * 1990-04-10 2000-01-31 Genentech Inc Compositions for cytoprotection against radiation and chemotherapy injury or risk thereof
WO1994021272A1 (fr) * 1993-03-17 1994-09-29 Amrad Corporation Limited Procede de traitement d'une infection microbienne chez un animal en lui administrant une composition comprenant lif et une cytokine
CN1180841C (zh) * 1999-09-30 2004-12-22 科研制药株式会社 胸骨切开术后促进胸骨愈合的方法
US10512708B2 (en) 2013-03-07 2019-12-24 Case Western Reserve University Bioadhesive hydrogels
US11273236B2 (en) 2016-09-07 2022-03-15 Case Western Reserve University Engineered tissue constructs
US11097034B2 (en) 2016-12-11 2021-08-24 Case Western Reserve University Compositions and methods of modulating endochondral ossification and bone formation
WO2019040224A1 (fr) 2017-08-21 2019-02-28 Case Western Reserve University Hydrogel pour l'ingénierie tissulaire et la bio-impression
US11191871B2 (en) 2018-03-30 2021-12-07 Case Western Reserve University Particulate coated hydrogel microparticles

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4438032A (en) * 1981-01-30 1984-03-20 The Regents Of The University Of California Unique T-lymphocyte line and products derived therefrom
US4675295A (en) * 1981-10-28 1987-06-23 Denki Kagaku Kogyo Kabushiki Kaisha Process for producing subculturable lymphokine-producing human T cell hybridomas
AU609128B2 (en) * 1987-04-02 1991-04-26 Amrad Operations Pty. Limited Leukaemia-inhibitory factor

Also Published As

Publication number Publication date
WO1990010454A1 (fr) 1990-09-20
EP0463004A4 (en) 1992-04-01
JPH04503958A (ja) 1992-07-16
EP0463004A1 (fr) 1992-01-02
NZ232826A (en) 1992-09-25
JP3055802B2 (ja) 2000-06-26

Similar Documents

Publication Publication Date Title
Nicola et al. Identification of the human analogue of a regulator that induces differentiation in murine leukaemic cells
Häuselmann et al. The superficial layer of human articular cartilage is more susceptible to interleukin‐1–induced damage than the deeper layers
Shen et al. NS-398, a cyclooxygenase-2-specific inhibitor, delays skeletal muscle healing by decreasing regeneration and promoting fibrosis
Botnick et al. Differential effects of cytotoxic agents on hematopoietic progenitors
Nickoloff et al. Additive and synergistic antiproliferative effects of cyclosporin A and gamma interferon on cultured human keratinocytes.
Faruqi et al. Distinct mechanisms for N-acetylcysteine inhibition of cytokine-induced E-selectin and VCAM-1 expression
McGlave et al. Therapy of chronic myelogenous leukemia with allogeneic bone marrow transplantation.
EA014644B1 (ru) Способы защиты от апоптоза с применением липопептидов
EP1263464B1 (fr) Emploi d'anticorps antagonistes contre le tgf-beta dans le traitement ou la prévention de la perte de la fonction renale
Rocker et al. 1, 25-Dihydroxyvitamin D3 potentiates the cytotoxic effect of TNF on human breast cancer cells
Tang et al. Transferrin but not albumin mediates stimulation of complement C3 biosynthesis in human proximal tubular epithelial cells
Merckx et al. Absence of system xc− on immune cells invading the central nervous system alleviates experimental autoimmune encephalitis
CA2048673A1 (fr) Effets metaboliques du facteur d'inhibition de la leucemie sur les os
Strassmann et al. Regulation of colony-stimulating factor 1-dependent macrophage precursor proliferation by type beta transforming growth factor.
US5730976A (en) Method for treating macrophage pathogen infections by TGF-B antagonists
Heusschen et al. Molecular mechanisms, current management and next generation therapy in myeloma bone disease
CA2513251C (fr) Sensibilisant d'une therapie de cancer
CA2284001A1 (fr) Agents cytoprotecteurs comprenant des inhibiteurs de monoamine-oxydase
Porcellini et al. Limiting-dilution analysis for the determination of leukemic cell frequencies after bone marrow decontamination with mafosfamide or merocyanine 540
Shuto et al. Granulocyte-macrophage colony stimulating factor suppresses lipopolysaccharide-induced osteoclast-like cell formation in mouse bone marrow cultures
Alfred Yung et al. Growth inhibitory effect of recombinant α and β interferon on human glioma cells
EP0521914B1 (fr) Procede de regulation du developpement et du maintien des neurones
Coggle Effect of cell cycle on recovery from radiation damage in the mouse liver
Garcia et al. Effects of synthetic peptido‐leukotrienes on bone resorption in vitro
JP2574962B2 (ja) 血小板減少症の処置方法及びそれに対し有用な医薬組成物

Legal Events

Date Code Title Description
FZDE Dead